Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Researchers, led by the University of Melbourne's Professor Laura Mackay, a Laboratory Head and Immunology Theme Leader at the Peter Doherty Institute of Infection and Immunity (Doherty Institute), in ...

The Crimson spoke to a range of commercial realtors, startup founders, and a commercial lab space owner to understand how the immense draw of Kendall Square has forced the myriad startup companies ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

NEW HAVEN, Conn., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company ...

AbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.

Currently chief information officer at Quest Diagnostics, Fonseca will join Pfizer’s executive leadership team in January. Fonseca previously served as senior vice president at Laboratory ...

Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced additional follow-up ...

Fonseca joined Pfizer in 2019, bringing more than 20 years ... venture has emerged from the Google DeepMind team, Latent Labs, with $50m in funding for its protein design platform.

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

He also underscored a recent statement from Presidential Secretary Álvaro Delgado regarding the commitment of the Pfizer laboratory to add technological advances to the batches of vaccines to be ...